Deltex Medical Group plc

Deltex Medical Group plc, established in 2000 and headquartered in Chichester, UK, specializes in the development, marketing, and distribution of oesophageal Doppler haemodynamic monitoring systems. These TrueVue-branded solutions are available across the United Kingdom, United States, Spain, Canada, and other international territories. The company's product line includes Esophageal Doppler Probes, which offer real-time insights into central vascular blood flow and fluid status by measuring blood velocities in the descending aorta. Loops graphically illustrates aortic blood flow velocity and pressure throughout each heartbeat, while High Definition Impedance Cardiography provides non-invasive monitoring of cardiac function and fluid balance for conscious patients. Additionally, PressureWave utilizes a pulse pressure waveform analysis algorithm, designed for use during patient instability or when the primary ODM mode is inaccessible. Deltex Medical also supports professional development with its Esophageal Doppler Simulator, allowing clinicians to refine their skills in probe insertion, focusing, and waveform interpretation in a controlled, non-patient environment. These sophisticated monitoring tools are crucial in various medical applications, including intensive care for COVID-19 patients, sepsis management, major surgical procedures (such as abdominal, laparoscopic, and spinal surgeries), cardiac interventions, trauma care, organ transplantation, and post-operative monitoring for acute kidney injury.

Deltex Medical Group plc trades as DEMG.L on LSE. The company is classified in Healthcare / Medical - Devices and reports in GBP.

The current profile places the business in Medical - Devices. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows £1.78M of revenue and -£1.28M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Deltex Medical Group plc can be compared against peers such as DeepVerge plc, Kanabo Group Plc, LungLife AI, Inc., LungLife AI, Inc., Oxford Cannabinoid Technologies Holdings Plc, Oncimmune Holdings plc.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of £663,609, beta of 0.63, and return on equity of -39.0%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

DEMG.L currently shows total debt of £1.92M and beta of 0.63. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.deltexmedical.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.